104 stories across all digests
Regulatory coverage on Peptide News Digest tracks how the FDA, MHRA, EMA, and state agencies handle peptides — what they let through, what they pull, what they redefine.
The compounding fight has dominated 2025 and 2026. GLP-1s came off the FDA shortage list in early 2025; the agency moved compounded semaglutide and tirzepatide toward Category 2 on the 503A bulks list; and a wave of state legislation tried to either preserve or shut off telehealth access. The PCAC has spent meetings on BPC-157, GHK-Cu, and other research peptides that have built consumer demand without clinical infrastructure behind them.
Stories here name the agency, the substance, and the action. Browse the latest below, or jump to specific tags like #fda, #compounding, #peptide-policy, or #503a.
A federal grand jury indicted Utah osteopathic physician Justin Bradley Watkins for obtaining non-FDA-approved peptides including tirzepatide, semaglutide, BPC-157, and retatrutide from a Chinese supplier, affixing fake labels, and selling them to over 200 patients without disclosing their unapproved status.
The FDA granted Apotex Corp. the first-ever tentative approval for a generic semaglutide injection equivalent to Ozempic/Wegovy. Actual market entry is blocked by Novo Nordisk patents until ~2032, but the milestone proves a complex peptide injectable can meet FDA generic equivalence standards.
Novo Nordisk received accelerated FDA approval for Wegovy HD, a higher-dose injectable semaglutide offering ~21% weight loss, with aggressive discount pricing to fight Lilly's market share gains.
HHS Secretary RFK Jr. announced 14 previously restricted peptides — including BPC-157, TB-500, CJC-1295, Ipamorelin, and AOD-9604 — are being moved from Category 2 back to Category 1, restoring legal compounding pharmacy access.
The FDA is intensifying enforcement against compounding pharmacies selling unapproved GLP-1 products, threatening seizure and injunction. Hims & Hers was specifically named following the February 2026 TrumpRx launch.
Health Canada warned Canadians against injecting unauthorized peptides purchased online, citing risks of organ damage and infection from products misleadingly labeled 'For Research Use Only.'
Semaglutide injections officially removed from the FDA drug shortage list, though localized availability issues persist. Tirzepatide shortage status remains contested by the Outsourcing Facilities Association.
Health Canada issued a public advisory warning against unauthorized injectable peptide drugs sold online for weight loss, anti-aging, and bodybuilding. Seized products include BPC-157, CJC-1295, retatrutide, and others, with cited risks of liver/kidney damage, blood clots, and cancerous tumours.
In-depth feature on peptide mania in wellness culture. HHS Secretary RFK Jr. wants to make unapproved wellness peptides more available to the public. The piece distinguishes FDA-regulated peptides from the largely untested 'wellness' peptides embraced by those mistrustful of mainstream medicine.
Based on analysis of 107,910 patients, the FDA concluded there is no increased suicide risk associated with GLP-1 medications and has requested removal of related warning labels.
A Utah physician was indicted for importing and selling misbranded drugs from China to over 200 patients. Customs separately seized 5,000 unapproved peptide units at the border.
The UK's MHRA is investigating peptide clinics promoting BPC-157, MOTS-C, and Cortexin with unproven claims. Making medicinal claims classifies these products as medicines under UK law.
The FDA published warning letters targeting companies marketing GLP-1 receptor agonists without regulatory approval, addressing CGMP violations and clinical trial protocol failures.
Labs report about a third of peptide products fail basic quality checks as the underground market explodes. Texas-based Finnrick processes ~60,000 samples per year, up from a handful per month.
MEDVi, a $1.8B AI-powered telehealth company with just two full-time employees, received an FDA warning letter in February 2026 for misbranding compounded semaglutide and tirzepatide.
The UK's medicines regulator is investigating whether clinics are breaking the law by making unsubstantiated medicinal claims for unregulated peptide therapies.
Three former officials maintain the 2023 decision to deem 19 peptides unsafe for compounding was grounded in documented safety concerns, countering Kennedy's claims on Joe Rogan.
The MHRA is investigating whether UK peptide clinics are breaking the law by making medicinal claims for unregulated peptides like BPC-157 and Thymosin Alpha. Clinics were found charging £350–£450/month per peptide despite labeling them "research only."